Div. of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth Univ. and McGuire VA Medical Ctr., 1201, Broad Rock Blvd., Richmond, VA 23249, USA.
Am J Physiol Gastrointest Liver Physiol. 2012 Jan 1;302(1):G168-75. doi: 10.1152/ajpgi.00190.2011. Epub 2011 Sep 22.
Hepatic encephalopathy (HE) has been related to gut bacteria and inflammation in the setting of intestinal barrier dysfunction. We aimed to link the gut microbiome with cognition and inflammation in HE using a systems biology approach. Multitag pyrosequencing (MTPS) was performed on stool of cirrhotics and age-matched controls. Cirrhotics with/without HE underwent cognitive testing, inflammatory cytokines, and endotoxin analysis. Patients with HE were compared with those without HE using a correlation-network analysis. A select group of patients with HE (n = 7) on lactulose underwent stool MTPS before and after lactulose withdrawal over 14 days. Twenty-five patients [17 HE (all on lactulose, 6 also on rifaximin) and 8 without HE, age 56 ± 6 yr, model for end-stage liver disease score 16 ± 6] and ten controls were included. Fecal microbiota in cirrhotics were significantly different (higher Enterobacteriaceae, Alcaligeneceae, and Fusobacteriaceae and lower Ruminococcaceae and Lachnospiraceae) compared with controls. We found altered flora (higher Veillonellaceae), poor cognition, endotoxemia, and inflammation (IL-6, TNF-α, IL-2, and IL-13) in HE compared with cirrhotics without HE. In the cirrhosis group, Alcaligeneceae and Porphyromonadaceae were positively correlated with cognitive impairment. Fusobacteriaceae, Veillonellaceae, and Enterobacteriaceae were positively and Ruminococcaceae negatively related to inflammation. Network-analysis comparison showed robust correlations (all P < 1E-5) only in the HE group between the microbiome, cognition, and IL-23, IL-2, and IL-13. Lactulose withdrawal did not change the microbiome significantly beyond Fecalibacterium reduction. We concluded that cirrhosis, especially when complicated with HE, is associated with significant alterations in the stool microbiome compared with healthy individuals. Specific bacterial families (Alcaligeneceae, Porphyromonadaceae, Enterobacteriaceae) are strongly associated with cognition and inflammation in HE.
肝性脑病 (HE) 与肠道屏障功能障碍时的肠道细菌和炎症有关。我们旨在使用系统生物学方法将肠道微生物组与 HE 中的认知和炎症联系起来。对肝硬化患者和年龄匹配的对照组的粪便进行多标签焦磷酸测序 (MTPS)。对有/无 HE 的肝硬化患者进行认知测试、炎症细胞因子和内毒素分析。使用相关网络分析将 HE 患者与无 HE 患者进行比较。对一组选择的 HE 患者(n=7)进行乳果糖治疗,在 14 天内停用乳果糖前后进行粪便 MTPS。共纳入 25 名患者[17 名 HE(均接受乳果糖治疗,6 名还接受利福昔明治疗)和 8 名无 HE,年龄 56±6 岁,终末期肝病模型评分 16±6]和 10 名对照组。与对照组相比,肝硬化患者的粪便微生物群明显不同(肠杆菌科、产碱杆菌科和梭杆菌科较高,而拟杆菌科和lachnospiraceae 较低)。与无 HE 的肝硬化患者相比,我们发现 HE 患者的菌群发生改变(肠球菌科较高),认知能力下降,内毒素血症和炎症(IL-6、TNF-α、IL-2 和 IL-13)。在肝硬化组中,产碱杆菌科和卟啉单胞菌科与认知障碍呈正相关。梭杆菌科、肠球菌科和肠杆菌科与炎症呈正相关,而拟杆菌科与炎症呈负相关。网络分析比较仅显示在 HE 组中,微生物组、认知和 IL-23、IL-2 和 IL-13 之间存在稳健的相关性(均 P<1E-5)。停用乳果糖后,除了降低粪杆菌外,微生物组没有明显变化。我们的结论是,与健康个体相比,肝硬化,尤其是伴有 HE 的肝硬化,与粪便微生物组的显著改变有关。特定的细菌家族(产碱杆菌科、卟啉单胞菌科、肠杆菌科)与 HE 中的认知和炎症密切相关。